Abstract
A review of the data from studies of oral contraceptives on coagulation and the fibrinolytic enzyme systems reveal an increase of a variety of coagulation factors. This is dose dependent and related to estrogens and appreciable above a dose of 0.5 micrograms of ethynylestradiol. Smaller amounts are less effective or not at all active. The mechanism of this increase is unknown. The pathophysiological significance is not yet clear. There is no available data that associate the increase of coagulation factors with disseminated intravascular coagulation. Conclusive evidence that low dose progesterone has any effect on the coagulation system is lacking.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
